Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma

Otolaryngol Head Neck Surg. 2007 Oct;137(4):647-53. doi: 10.1016/j.otohns.2007.05.063.

Abstract

Objective: Prospectively evaluate the impact of fluorodeoxyglucose-fluorine-18 positron emission tomography (FDG-PET) in the management of recurrence of advanced head and neck squamous cell carcinoma during the first year after treatment.

Study design: Seventy patients were followed-up every 6 to 8 weeks during the first year after initial combined curative therapy. FDG-PET, together with conventional imaging and endoscopy were performed systematically at 1 year (group A) or prompted earlier in case of clinically suspicious recurrence (group B). The referring physician evaluated the impact of FDG-PET on the patient's management. Another clinician checked the pertinence of decisions.

Results: FDG-PET had a therapeutic impact in 8 of 43 group A patients and in 16 of 27 group B patients; the overall rate was 34%. This change was pertinent in 5 of 8 and 14 of 16 cases, respectively. Overall pertinence rate of decisions was 90% versus 70% without FDG-PET.

Conclusions: FDG-PET had a significant overall therapeutic impact; the induced decisions were either pertinent or just led to "futile" noninvasive examinations. Systematic FDG-PET had a significantly lesser impact in comparison with FDG-PET motivated by clinical suspicion.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell / diagnostic imaging*
  • Carcinoma, Squamous Cell / secondary
  • Decision Making
  • Endoscopy
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Head and Neck Neoplasms / diagnostic imaging*
  • Humans
  • Hypopharyngeal Neoplasms / diagnostic imaging
  • Laryngeal Neoplasms / diagnostic imaging
  • Lymphatic Metastasis / diagnostic imaging
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Oropharyngeal Neoplasms / diagnostic imaging
  • Positron-Emission Tomography / methods*
  • Prospective Studies
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18